Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 1.53 g/t Au over 191.3m in infill drilling at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ELDN)

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

GlobeNewswire 3 days ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

GlobeNewswire November 18, 2025

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

GlobeNewswire November 14, 2025

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 12, 2025

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 11, 2025

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

GlobeNewswire November 6, 2025

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

GlobeNewswire November 5, 2025

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

GlobeNewswire October 17, 2025

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

GlobeNewswire September 24, 2025
View More News ››

Opinion & Analysis (NDAQ:ELDN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ELDN)

ELDN - Thursday Rundown, Friday Expectations

<< View Post To Watch Video >>
HDavis - November 11, 2021

Is a Cure for Diabetes Being Studied

Is a Cure for Diabetes Enetering Phase II Trials? https://www.channelchek.com/news-channel/Is_a_Cure_for_Diabetes_Being_Studied_
SmallCapPaul - December 11, 2020

Functional Cure for T1D Discussion

Noble Capital Markets, Inc. Announces Type-1 Diabetes Day- The Beginning of the End; Close to a Cure?   A Panel of World...
SmallCapPaul - November 23, 2020

Novus Acquires Anelixis Therapeutics

Acquisition includes lead clinical-stage compound AT-1501, a next generation anti-CD40L antibody, in development for organ and cellular...
schoolofrock - September 15, 2020

Nice Move Today

This should be a good one. Phase 1 but very promising imho.
dmacd - January 22, 2019
View more Bullboard ››

Lipari Mining Ltd.

Lipari Mining Ltd.

Lipari Mining is a natural diamond producer from its 100% owned Braúna diamond mine in Brazil. The Braúna mine is the only ...
View More »